



Two amino acids in each of D₁ and D₂ dopamine receptor cytoplasmic regions are involved in D₁–D₂ heteromer formation

Brian F. O'Dowd^{a,b,*}, Xiaodong Ji^b, Tuan Nguyen^{a,b}, Susan R. George^{a,b,c}

^a Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada M5S 1A8

^b Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada M5S 1A8

^c Department of Medicine, University of Toronto, Toronto, Ontario, Canada M5S 1A8

ARTICLE INFO

Article history:

Received 28 October 2011

Available online 12 November 2011

Keywords:

G protein coupled receptors

Dopamine receptor

Nuclear localization

Protein structure

Heteromer

Interacting amino acids

ABSTRACT

D₁ and D₂ dopamine receptors exist as heteromers in cells and brain tissue and are dynamically regulated and separated by agonist concentrations at the cell surface. We determined that these receptor pairs interact primarily through discrete amino acids in the cytoplasmic regions of each receptor, with no evidence of any D₁–D₂ receptor transmembrane interaction found. Specifically involved in heteromer formation we identified, in intracellular loop 3 of the D₂ receptor, two adjacent arginine residues. Substitution of one of the arginine pair prevented heteromer formation. Also involved in heteromer formation we identified, in the carboxyl tail of the D₁ receptor, two adjacent glutamic acid residues. Substitution of one of the glutamic acid pair prevented heteromer formation. These amino acid pairs in D₁ and D₂ receptors are oppositely charged, and presumably interact directly by electrostatic interactions.

© 2011 Elsevier Inc. All rights reserved.

1. Introduction

Family A G protein coupled receptors (GPCRs) form heteromers [1–3]. We reported that D₁–D₂ receptor heteromers exist in brain and cultured neurons [4,5]. We showed receptor activation within D₁–D₂ heteromers generated a Gq-mediated calcium signal [4,6,7]. We have determined that D₁–D₂ heteromers were subject to conformational changes and separation by dopamine or receptor-selective agonists [8]. We also reported that the D₁ and D₂ receptor heteromers reform at the cell surface when the agonist was removed [8]. These data provided evidence of the fate of a heteromer following agonist activation and demonstrated a unique regulation of GPCRs at the cell surface. However, many fine structural details of how D₁–D₂ heteromers dynamically interact remain unknown. In this report we have determined the precise amino acid interactions maintaining D₁ and D₂ receptors in a D₁–D₂ receptor complex. Our ultimate goal is the understanding of the physiological relevance of GPCR:GPCR heteromers, one of the leading questions in the GPCR field.

Progress in the fundamental area of GPCR oligomer structural investigation has been hampered by the lack of decisive methods for determining the interacting heteromer interface. We overcame technical challenges by the following process: a nuclear localization

sequence (NLS) was inserted into the D₂ receptor. Strategic placement of the NLS rendered this D₂–NLS receptor conformationally sensitive, so that interacting ligands retained the receptor at the cell surface [9]. D₂–NLS and the D₁ receptors were coexpressed and following ligand removal, the D₂–NLS receptor translocated with the D₁ receptor from the cell surface. We demonstrated that as the D₂–NLS receptor translocated with the D₁ receptor this provided a tool to study receptor:receptor dynamic interactions in a cell [9]. By this strategy we sought to reveal the structural basis for the D₁–D₂ receptor interaction. By co-expressing D₂–NLS and D₁ receptors the contributions of various cytoplasmic regions of these receptors to heteromer formation was investigated.

In this report, we have determined the precise amino acids in the cytoplasmic regions of both the D₁ and D₂ receptors involved in their heteromeric interactions. Activation of the heteromer contributes to conformational changes in the receptors within the oligomer. We have now identified these residues affected by agonist induced conformational changes. Also we identified that changing a single amino acid in the intracellular loop 3 of the D₂ receptor or in the carboxyl tail of the D₁ receptor prevented D₁–D₂ heteromer formation.

2. Materials and methods

2.1. Fluorescent proteins

cDNA sequences encoding GFP, RFP were obtained from Clontech (Palo Alto, CA), and the receptor constructs generated as described [9]. The YFP vector was obtained from BD Biosciences.

* Corresponding author at: Department of Pharmacology, University of Toronto, 1 King's College Circle, Room 4353, Toronto, Ontario, Canada M5S 1A8. Fax: +1 416 971 2868.

E-mail address: brian.odowd@utoronto.ca (B.F. O'Dowd).

2.2. Cell culture

HEK cells grown to confluence on 60 mm plates in minimum essential medium (MEM), and were transfected with 0.5–2 µg cDNA using Lipofectamine (Life Technologies, Rockville MD).

2.3. Microscopy

Live cells expressing GFP, RFP and YFP fusion proteins were visualized with a LSM510 Zeiss confocal laser microscope. In each experiment 5–8 fields, containing 50–80 cells per field were evaluated and the entire experiment was repeated several times ($n = 3–5$).

2.4. DNA constructs

All the DNA encoding the GPCRs were human origin. Sequences encoding GPCRs were cloned into plasmids pEGFP, as described previously [9]. The D₁ carboxyl tail DNA PCR product, containing no stop codon was subcloned into vector pYFP-N1 (BD Biosciences) at EcoR1 and Kpn1 and inframe with the start codon of YFP.

2.5. Receptor constructs

The D₁ and D₂ receptors were prepared using the Quickchange mutagenesis kit (Stratagene) according to the manufacturer's instructions, and as described [9]. Receptor DNA was subjected to PCR as previously reported [9]. The reaction mixture consisted of: H₂O (32 µl), 10× Pfu buffer (Stratagene) (5 µl), dNTP (10 mM, 5 µl), DMSO (5 µl), oligonucleotide primers (100 ng, 1 µl each), DNA template (100 ng), Pfu enzyme (5U). Total volume 50 µl. PCR conditions, one cycle at 94 °C for 2 min, 30–35 cycles at 94 °C for 30 s, 55 °C for 30 s, 72 °C for 1 min, per cycle, and then one cycle at 72 °C for 5 min. The NLS sequence was inserted into DNA encoding the D₁ and D₂ dopamine receptors by PCR [8].

2.6. Membrane preparation

Cells expressing D₂-NLS or D₁-NLS were washed with phosphate-buffered saline, resuspended in hypotonic lysis buffer (5 mM Tris-HCl, 2 mM EDTA, 5 µg/ml leupeptin, 10 µg/ml benzamide, 5 µg/ml soybean trypsin inhibitor, pH 7.4), and homogenized by Polytron (Brinkmann Instruments). The homogenate was centrifuged to pellet unbroken cells and nuclei. The supernatant centrifuged at 40,000g to obtain a membrane pellet.

2.7. Radioligand binding assays

Competition binding assays were performed as described previously [1,3]. Briefly, for competition experiments, 20–25 µg of membrane was incubated with 1 nM [³H]-raclopride (for D₂) or [³H]-SCH23390 (for D₁) (NEN Life Science Products) and increasing concentrations of competing drug. The reaction volume was 0.5 ml, and the binding buffer consisted of 50 mM Tris-HCl, 5 mM EDTA, 1.5 mM CaCl₂, 5 mM MgCl₂, 5 mM KCl, and 120 mM NaCl, pH 7.4. Nonspecific binding was defined using 1 µM (+)-butaclamol (Research Biochemicals International, Hercules, CA). Binding reactions were incubated at room temperature for 2 h to reach equilibrium. Bound radioligand was then isolated from free by rapid filtration through a Brandel 48-well harvester using Whatman GF/C filters. Data were analyzed using nonlinear least squares regression equations on the curve-fitting computer program Prism (Graphpad).

3. Results

3.1. Binding and expression properties of the D₂-NLS receptor and D₁-NLS receptors

The incorporation of NLS into the D₂ receptor did not alter the binding properties, with preserved agonist-detected high affinity and low affinity states, indicative of intact receptor-G protein coupling. The D₂ receptor had a K_{High} value of 1.51×10^{-9} M and K_{Low} of 6.67×10^{-6} M for quinpirole. Similarly the D₂-NLS receptor had a K_{High} value of 3.22×10^{-9} M and K_{Low} of 4.16×10^{-6} M for quinpirole [9].

The incorporation of the NLS into the D₁ receptor did not alter the binding pocket of the receptor, with preserved agonist-detected high affinity and low affinity states, indicative of intact receptor-G protein coupling and ligand affinities. The D₁-NLS receptor had a K_{high} value of 4.17×10^{-9} M and K_{Low} of 1.19×10^{-7} M detected by agonist SKF 81297 not different from unmodified D₁ receptor [9].

3.2. Identification of the D₂ dopamine receptor amino acids involved in D₁-D₂ heteromer formation

We wished to determine if amino acids located in the cytoplasmic loops of the D₂ receptor were involved in forming heteromeric complexes with the D₁ receptor. The D₂ receptor has an unusual GPCR structure in having no significant carboxyl tail, as the carboxyl tail terminates with the palmitoylated cysteine [10]. There are two forms of the D₂ dopamine receptor, namely D₂ long and D₂ short, differing by a 29 amino acid insert in ic3, located thirty amino acids from transmembrane 5 (TM5; Fig. 1) [11]. The very large intracellular D₂ receptor third loop (intracellular loop 3, ic3) contains ~160 amino acids, this region comprises 40% of the total receptor structure, Fig. 1. The D₂-NLS long receptor with a fully intact ic3 and the D₁ receptor are shown co-expressed in Fig. 2A, with significant co-translocation indicating robust heteromer formation.

In our strategy, initially working with the D₂ long receptor, we prepared a series of D₂ receptor constructs with deletions contained in this third loop (outlined in Table 1 and Fig. 1). Each of these ic3 receptor constructs of the D₂-NLS receptor were co-expressed with the D₁ receptor. In each case D₁-D₂ heteromerization was monitored by the ability of these D₂-NLS receptors to enable transportation of the D₁ receptor from the cell surface to the cytoplasm and nucleus. We first determined that a large deletion, L1, of 72 amino acids (Table 1 and Fig. 1), from the carboxyl terminal half of D₂ receptor ic3 had no effect on D₁-D₂ heteromer formation, these receptors translocated together (Fig. 2B). However, another D₂ receptor construct, L2, with 72 amino acids deleted from the amino terminal half of ic3 (Table 1 and Fig. 1) failed to show D₁-D₂ receptor co-translocation, and hence failed to form D₁-D₂ receptor heteromers, Fig. 2C. Thus data from the L2 construct indicated that amino acids maintaining heteromer formation were likely contained in this region. To locate the critical amino acids, portions of this ic3 L2 region were serially deleted to identify regions involved in the interaction with the D₁ receptor.

We divided the L2 region into two parts, L3 (24 amino acids) and L4 (19 amino acids, Fig. 1), not including the 29 amino acid insert of the D₂ long receptor. The construct L4 formed D₁-D₂ receptor heteromers while construct L3 did not (L3 shown in Fig. 2D), thus the region involved in heteromer formation was contained in the 24 amino acids of construct L3. The L3 region was divided in two equal parts, with constructs L5 and L6. Only construct L6 failed to form heteromers with the D₁ receptor and this region of 12 amino acids was further divided in two equal parts, in




Fig. 1. Representation of the of the primary amino acid sequence of the cytoplasmic intracellular tail of the D_1 dopamine receptor and the primary amino acid sequence of the large cytoplasmic intracellular third loop of the D_2 dopamine receptor. The locations of the various intracellular deletions constructs are shown, numbers in bracket indicate amino acids deleted. The position of the insert of 29 amino acids in the D_2 long receptor is indicated by the shading.




Fig. 2. Visualization of co-expression of D_1 and D_2 -NLS dopamine receptors. (A) D_2 -NLS (GFP) (green) and D_1 (RFP) (red) co-translocated to the cytoplasm and nucleus. (B) L1 (D_2 -NLS) (GFP) (green) and D_1 (RFP) (red) co-translocated to the cytoplasm and nucleus. (C) L2 (D_2 -NLS) (GFP) (green) and D_1 (RFP) (red) did not co-translocate. (D) L3 (D_2 -NLS) (GFP) (green) and D_1 (RFP) (red) did not co-translocate. (E) L8 (D_2 -NLS) (GFP) (green) and D_1 (RFP) (red) did not co-translocate. (F) L9 (D_2 -NLS) (GFP) (green) and D_1 (RFP) (red) did not co-translocate. Each size bar in figures showing cells indicates length of 10 μ m.

Table 1
D₂ dopamine receptor constructs.

D ₂	Receptor constructs	Heteromer formation
L1	...PPERTR(<i>YSPIP</i> ... <i>LSQQ</i>)KEKK...	Yes
L2	...RRRRKR(<i>VNTK</i> ... <i>ERTR</i>)YSPI...	No
L3	...VNRRRV(<i>EAARRA</i> ... <i>ERTR</i>)YSPI...	No
L4	...RRRRKR(<i>VNTKR</i> ... <i>APLK</i>)GNCT...	Yes
L5	...QELEME(<i>MLSSTSPPERTR</i>)YSPI...	Yes
L6	...VNRRRV(<i>EAARRAQELEME</i>)MLSS...	No
L7	...EAARRA(<i>QELEME</i>)MLSS...	Yes
L8	...VNRRRV(<i>EAARRA</i>)QELE...	No
L9	...VNRRRV <i>EAAAAA</i> QELE...	No
L10	...VNRRRV <i>AAARRA</i> QELE...	Yes
L11	...VNRRRV <i>EAARAA</i> QELE...	No
L12	...VNRRRV <i>EAAARA</i> QELE...	No
L13	...VNRRRV <i>EAAKKA</i> QELE...	No
L14	...MKLCTV(<i>IMKSNCSFPVNRRRVE</i>)AARR...	Yes
L15	...KIYIVL <i>AAAAAA</i> VNTK...	Yes

Amino acid sequence in *italics*, underlined and brackets indicates deletions.
Amino acid sequence in *italics*, and underlined indicates substitutions.

constructs L7 and L8. Construct L8, with the sequence (271-EAARRA) deleted, also failed to form heteromers with the D₁ receptor, Fig. 2E.

Thus as a result of following this systematic process we successfully narrowed the ic3 region of D₂ receptor that was required for interacting with the D₁ receptor to 6 amino acids (271-EAARRA). The start of this sequence was located a distance of 59 amino acids from TM5 (Fig. 1), of the D₂ long receptor. By substituting the three charged amino acids in this sequence, L9 (EAAAAA), Fig. 2F, and L10 (AAARRA), we determined that the vicinal arginine residues alone (274-RR) were the key residues required for heteromerization with the D₁ receptor. Substitution of the glutamic acid residue had no effect on the D₁–D₂ heteromerization, L10. We examined the role of each arginine residue separately, we prepared two D₂-NLS constructs, namely L11 (EAARAA) and L12 (EAAARA), compared to wild type-EAARRA. Co-expression of L11 and L12 receptor constructs with the D₁ receptor failed to show heteromerization, thus demonstrating that a single amino acid change prevented D₁–D₂ receptor heteromer formation, and demonstrating that both arginine residues were required for heteromer formation. Also we prepared a D₂-NLS construct L13 (EAAKKA), where the vicinal arginines were replaced by similarly charged lysines. Co-expression of this construct failed to show heteromer formation with the D₁ receptor. Thus from a total structure of the ~160 amino acids in ic3 loop of the D₂ receptor only two specific charged amino acids (274-RR) were involved in forming heteromers with the D₁ receptor.

3.3. Role of D₂ long and D₂ short dopamine receptors

As stated there are two forms of the D₂ dopamine receptor, namely D₂ long and D₂ short, differing by a 29 amino acid insert in ic3, located thirty amino acids from TM5 (Fig. 1) [11]. A recent report [12] stated that D₁ and D₂ receptors interacted via a section of these 29 residues, thus implying that D₂ short receptor could not form heteromers with the D₁ receptor. To investigate we co-expressed the D₁-NLS receptor with the D₂ short receptor and showed them to be capable of forming heteromers, Fig. S1A. This result we expected as the significant region we identified in ic3 of D₂ receptor (274-RR), was present in both the D₂ long and D₂ short receptors.

Specifically, it was pinpointed that a sequence of 15 amino acids in the carboxyl part of this 29 amino acids in ic3 of the D₂ long receptor interacted directly with the D₁ receptor [12]. Thus we

prepared a D₂-NLS receptor construct, L14, where we deleted these 15 amino acids (Table 1, Fig. 1). However this D₂-NLS receptor, L14, was also capable of forming D₁–D₂ heteromers, Fig. S1B.

3.4. Investigation of the role of the D₂ receptor intracellular loop 3 region 217-RRRRKR

In several previous reports, the D₂ ic3 region 217-RRRRKR was implicated as the possible heteromer interacting site, forming heteromers with either D₁ dopamine [13], 5HT_{2A} serotonin [14] or adenosine A_{2A} receptors [15]. This highly charged amino sequence starts at a distance of six amino acids from TM5. We substituted this 217-RRRRKR region in D₂-NLS receptor with alanines (construct L15, Table 1). Coexpression of L15 with the D₁ receptor demonstrated co-translocation, and hence intact heteromer formation, Fig. S1C.

3.5. Identification of the D₁ dopamine receptor amino acids involved in D₁–D₂ heteromer formation

We wished to determine if amino acids located in any of the cytoplasmic loops or carboxyl tail of the D₁ dopamine receptor were involved in forming heteromers with the D₂ dopamine receptor. The D₁ receptor has an extensive carboxyl tail, extending ~114 amino acids from the palmitoylated cysteine (26% of the total D₁ receptor). Initially D₁ and D₂-NLS receptors were co-expressed with a construct containing the entire D₁-carboxyl tail (Table 2). In the presence of the D₁-carboxyl tail construct, the D₁ and D₂-NLS receptors did not form heteromers, indicating that the amino acids in the carboxyl tail were involved in heteromer formation, Fig. S2A. Consequently we prepared a series of deletions constructs in the D₁ carboxyl tail (C1–C5), and each deletion construct was co-expressed with the D₂-NLS receptor (Table 2 and Fig. 1). Of these D₁ carboxyl tail deletion constructs only C4, failed to show receptor heteromerization, indicating the location of a 12 amino acid critical region involved in D₁–D₂ heteromer formation. In this sequence the deletion of 6 amino acids (GSSEDL; Fig. 1), C6, had no effect on heteromer formation with the D₂ receptor.

Thus, by this process we narrowed the critical sequence to 6 amino acids (402-KKEEAA), Fig. 1. The start of this discrete region of the

Table 2
D₁ dopamine receptor constructs.

D1	Receptor constructs	Heteromer formation
C1	...YDITDVS(<i>LEKIOPITONGOHPT</i>)	Yes
C2	...EKLSPA(<i>LSVILDYDITDVSLEKIOPITONGOHPT</i>)	Yes
C3	...KKEEAA(<i>GIARPLEKLSPA</i>)LSVI...	Yes
C4	...IPHAV(<i>GSSEDLKKEEAA</i>)GIAR...	No
C5	...SISKEC(<i>NLVYLIPHAV</i>)GSSE...	Yes
C6	...IPHAV(<i>GSSEDL</i>)KKEE...	Yes
C7	...GSSEDL(<i>KKEEAA</i>)GIAR...	No
C8	...GSSEDL <i>AAAAA</i> GIAR...	No
C9	...GSSEDLKKEELL GIAR...	Yes
C10	...GSSEDL(<i>KKEE</i>)AAGIAR...	No
C11	...GSSEDLKK <i>DA</i> AAGIAR...	No
C12	...GSSEDL <i>A</i> KKEEAAGIAR...	Yes
C13	...GSSEDLK <i>A</i> EAAAGIAR...	Yes
C14	...GSSEDLKKE <i>A</i> AAGIAR...	No
C15	...GSSEDLKK <i>A</i> EAAAGIAR...	No
C16	...GSSEDLKK <i>AA</i> AAGIAR...	–
C17	...GSSEDL <i>AA</i> EAAAGIAR...	–

D₁-Carboxyl tail: MAFSTLLGCYRLCP... (86 amino acids)... TQNGQHPT

Amino acid sequence in *italics*, underlined and brackets indicates deletions.
Amino acid sequence in *italics*, and underlined indicates substitutions.

D₁ carboxyl tail is located 68 amino acids from TM7. In construct C7 this sequence was deleted and in construct C8 this sequence was substituted by alanines; in neither case was heteromer formation observed with the D₂ receptor. Substitution of the alanine pair in this region, C9, had no effect on the heteromer formation. However the deletion of four amino acids (KKEE), C10, D₂ receptor heteromer formation was not observed, Fig. S2B. By substituting the amino acids in this sequence (402-KKEE) we determined that the glutamic acid pair alone were the key residues required for D₁–D₂ heteromers. We prepared a construct with a similar charged pair of aspartic acid residues (DD) substituting for (EE), C11, and this receptor did not form D₁–D₂ heteromers, Fig. S2C. We prepared two single amino acid substitution D₁ constructs, C12 (AKEE) and C13 (KAE) and co-expressed each with the D₂-NLS receptor, D₁–D₂ heteromer formation was observed, Figs. S2D and S2E. We prepared the receptors, C14 (KKEA) and C15 (KKAE), where one glutamic acid was substituted, in each case no D₁–D₂ heteromerization was observed. Thus from a total structure of 114 amino acids in this D₁ carboxyl tail only a pair of glutamic acid residues were required for forming a heteromer with the D₂ receptor.

Further analysis of the –KKEE– sequence with constructs C16 and C17 prepared with the two lysines (KK) deleted, or with the two glutamic acids deleted (EE) gave very poor expression, without any result.

4. Discussion

There are several significant and unique accomplishments regarding the oligomeric structures of the D₁–D₂ dopamine receptors reported here. (i) We determined that a pair of adjacent arginines of the D₂ receptor, located in the third cytoplasmic loop, were involved in forming heteromers with the D₁ receptor. (ii) We determined that both arginines were required, a D₂ receptor with one of the arginines substituted did not form heteromers with the D₁ receptor. (iii) We determined that the oppositely charged pair of glutamic acids located in the D₁ receptor carboxyl tail was involved in forming heteromers. (iv) We determined that both glutamic acids were required, a D₁ receptor construct with one of the glutamic acids substituted did not form heteromers with the D₂ receptor. (v) We determined that a construct with the vicinal aspartic acids substituted for the glutamic acids in the D₁ receptor carboxyl tail did not form heteromers. (vi) Both D₂ long and D₂ short dopamine receptors were capable of forming heteromers with the D₁ receptor, and we found no evidence that any part of the 29 amino acid insert in D₂ long receptor was involved in heteromer formation. (vii) We found no evidence that transmembrane interactions were required in D₁–D₂ heteromer formation.

We have previously shown that D₁–D₂ heteromers separated into D₁ and D₂ receptors by agonist treatment. Agonist binding alters the receptor conformation and resulted in the separation of the components of the heteromer. It appears likely that with dopamine activation of the D₁–D₂ heteromer there is a conformational change in the D₂ intracellular third loop and D₁ carboxyl tail which disengages the interaction between these receptors, perhaps disrupting a direct D₁–D₂ (EE:RR) electrostatic interaction. Receptor-selective agonists bind and alter the conformation of either D₁ or D₂ dopamine receptors and this change also was sufficient to disrupt the heteromer. Thus conformational change in either the ic3 or carboxyl tail can cause heteromer disruption.

Thus the NLS incorporation strategy has enabled precise elucidation of structural features of D₁ and D₂ receptor heteromers, aspects of GPCR oligomer structure that were not resolved previously. This method can be applied for other members of this rhodopsin related family of receptors.

A recent report also implicated cytoplasmic regions in the formation of M3–M5 muscarinic receptor heteromers. Co-expression of the M3 and M5 receptors with a peptide from ic3 of the M5 receptor reduced the degree of heteromerization [16].

The role of the D₂ receptor ic3 217-RRRRKR sequence (Fig. 1) in heteromer formation with the D₁ receptor and with the 5HT2A receptors was investigated [13,14]. These investigators concluded only that this region might be involved, their report contained caveats due to possible altered intracellular location of the D₂ dopamine receptor with the removal of this arginine rich region. Ciruela et al. [15] also investigated the role of this D₂ receptor (217-RRRRKR) region in heteromer formation with adenosine A2 receptors. They concluded that this ic3 region of the D₂ dopamine receptor formed part of that heteromer [15]. However, we found no evidence for a primary heteromer involvement as our deletion of 217-RRRRKR in the D₂ receptor ic3, L15, had no effect on the intact D₁–D₂ heteromer formation. Although we do understand that GPCR:GPCR interactions are complex and likely involve multiple contact sites.

We are in agreement with [13] the role of vicinal glutamic acids (404 EE) present in the D₁ carboxyl tail, as being involved in the D₁–D₂ heteromer. This glutamic acid pair is located 56 amino acid from the palmitoylated cysteine in the D₁ receptor. Interestingly a glutamic acid pair located in the 5HT2A receptor carboxyl tail was identified as being involved in D₂–5HT2A receptor heteromers [14]. This identified glutamic acid pair in the 5HT2A receptor was also located 56 amino acids from the palmitoylated cysteine. These results may indicate that the D₁ and 5HT2A receptor carboxyl tails are required to extend a similar distance to interact directly with the arginine pair in ic3 of the D₂ receptor.

The identified sites in the D₂ ic3 and D₁ carboxyl tail receptors as the heteromer forming site would require a proximity of these intracellular regions. These changes in cytoplasmic conformation will create other areas of heteromer contact. Formation of the D₁–D₂ heteromer likely changes the cytoplasmic architecture of these receptor pairs, due to this entanglement of the D₁ and D₂ cytoplasmic regions. These conformational changes enabled participation in G protein coupling of different signaling cascades by the D₁–D₂ heteromer [4].

Contrary to the implications of the data from [12] the D₂ short receptor formed heteromers with the D₁ receptor. Based on our data we did not find the ic3 29 amino acids, that differentiate D₂ long from D₂ short receptors, required for D₁–D₂ heteromer formation.

In summary, we used a novel approach to examine and elucidate the structure of D₁–D₂ receptor heteromers. As a result of the work described we are now in a position to prepare D₁ and D₂ receptor expressing cells engineered to be incapable of forming heteromers. The signaling properties of these unique cell lines will be of great interest, and this work will elucidate the true role of the heteromers in the physiology of receptor functioning as heteromers.

Acknowledgments

This work was partially supported by a Proof of Principle Grant from the Canadian Institutes for Health Research and National Institute on Drug Abuse Grant (DA007223). S.R.G. holds a Canada Research Chair in Molecular Neuroscience. The authors thank Hong Fan Qian for preparation of Fig. 1.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.bbrc.2011.11.027](https://doi.org/10.1016/j.bbrc.2011.11.027).

References

- [1] S.R. George, B.F. O'Dowd, S.P. Lee, G-protein-coupled receptor oligomerization and its potential for drug discovery, *Nat. Rev. Drug Discovery* 1 (2002) 808–820.
- [2] G. Milligan, G protein-coupled receptor dimerization: function and ligand pharmacology, *Mol. Pharm.* 66 (2004) 1–7.
- [3] F. Ciruela, A. Vallano, J.M. Arnau, S. Sánchez, D.O. Borroto-Escuela, L.F. Agnati, K. Fuxe, V. Fernández-Dueñas, G protein-coupled receptor oligomerization for what?, *J. Recept. Signal Transduct. Res.* 30 (2010) 322–330.
- [4] A. Hasbi, T. Fan, M. Alijanian, T. Nguyen, M.L. Perreault, B.F. O'Dowd, S.R. George, Calcium signaling cascade links dopamine D₁–D₂ receptor heteromer to striatal BDNF production and neuronal growth, *Proc. Natl. Acad. Sci. USA* 106 (2009) 21377–21382.
- [5] M.L. Perreault, A. Hasbi, M. Alijanian, T. Fan, G. Varghese, P.J. Fletcher, P. Seeman, B.F. O'Dowd, S.R. George, The dopamine D₁–D₂ receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia, *J. Biol. Chem.* 285 (2010) 36625–36634.
- [6] S.P. Lee, C.H. So, A.J. Rashid, G. Varghese, R. Cheng, A.J. Lança, B.F. O'Dowd, S.R. George, Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal, *J. Biol. Chem.* 279 (2004) 35671–35678.
- [7] A.J. Rashid, C.H. So, M.M. Kong, T. Furtak, M. El-Ghundi, R. Cheng, B.F. O'Dowd, S.R. George, D₁–D₂ dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum, *Proc. Natl. Acad. Sci. USA* 104 (2007) 654–659.
- [8] B.F. O'Dowd, X. Ji, M. Alijanian, T. Nguyen, S.R. George, Separation and reformation of cell surface dopamine receptor oligomers visualized in cells, *Eur. J. Pharmacol.* 658 (2011) 74–83.
- [9] B.F. O'Dowd, X. Ji, M. Alijanian, R.D. Rajaram, M.M. Kong, A. Rashid, T. Nguyen, S.R. George, Dopamine receptor oligomerization visualized in living cells, *J. Biol. Chem.* 280 (2005) 37225–37235.
- [10] J.R. Bunzow, H.H. Van Tol, D.K. Grandy, P. Albert, J. Salon, M. Christie, C.A. Machida, K.A. Neve, O. Civelli, Cloning and expression of a rat D2 dopamine receptor cDNA, *Nature* 336 (1988) 783–787.
- [11] B.F. O'Dowd, T. Nguyen, A. Tirpak, K.R. Jarvie, Y. Israel, P. Seeman, H.B. Niznik, Cloning of two additional catecholamine receptors from rat brain, *FEBS Lett.* 262 (1990) 8–12.
- [12] L. Pei, S. Li, M. Wang, M. Diwan, H. Anisman, P.J. Fletcher, J.N. Nobrega, F. Liu, Uncoupling the dopamine D₁–D₂ receptor complex exerts antidepressant-like effects, *Nat. Med.* 16 (2010) 1393–1395.
- [13] S. Łukasiewicz, A. Faron-Górecka, J. Dobrucki, A. Polit, M. Dziedzicka-Wasylewska, Studies on the role of the receptor protein motifs possibly involved in electrostatic interactions on the dopamine D1 and D2 receptor oligomerization, *FEBS J.* 276 (2009) 760–775.
- [14] S. Łukasiewicz, A. Polit, S. Kędracka-Krok, K. Wędzony, M. Maćkowiak, M. Dziedzicka-Wasylewska, Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors, *Biochim. Biophys. Acta* 1803 (2010) 1347–1358.
- [15] F. Ciruela, J. Burgueño, V. Casadó, M. Canals, D. Marcellino, S.R. Goldberg, M. Bader, K. Fuxe, L.F. Agnati, C. Lluís, R. Franco, S. Ferré, A.S. Woods, Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors, *Anal. Chem.* 76 (2004) 5354–5363.
- [16] D.O. Borroto-Escuela, G. García-Negredo, P. Garriga, K. Fuxe, F. Ciruela, The M(5) muscarinic acetylcholine receptor third intracellular loop regulates receptor function and oligomerization, *Biochim. Biophys. Acta* 1803 (2010) 813–825.